The advanced protocol should only be implemented after successful tolerance of lower doses and under appropriate medical supervision
Method of Use: Dosage and duration of treatment should be supervised by a healthcare professional, adapting to the severity of each case (e.g., diabetic neuropathy or sciatica)
CohBar completes phase 1a and initiates phase 1b stage of clinical trial of CB4211 under development for NASH and ObesityMilestone for first mitochondrial based therapeutic in humans
Others Before receiving B 29 AQ 1500MCG PREFILLED SYRINGE(PFS), inform your doctor if you: have Leber's disease (inherited form of vision loss) have signs of low potassium level in blood such as muscle twitches/cramps, low blood pressure, faintness and/or excessive urination/thirst are suffering from optic nerve disease (swelling and nerve damage to the eyes)
Observations are model-dependent and exploratory
GLP-1 therapy is generally not recommended during breastfeeding due to theoretical concerns about infant exposure and caloric restriction during lactation